AbbVie Inc.

09/12/2024 | Press release | Distributed by Public on 09/12/2024 17:00

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.